FDA approves Chiesi’s Trimbow triple-therapy inhaler for adult asthma maintenance

  • Chiesi USA secured U.S. FDA clearance for TRIMBOW, a single-inhaler triple therapy for maintenance treatment of asthma in adults.
  • The label covers two strengths dosed as two inhalations twice daily; the product is not indicated for acute relief.
  • Approval was supported by Phase 3 TRIMARAN and TRIGGER trials in more than 2,200 adults with uncontrolled asthma, showing improved lung function versus beclomethasone/formoterol.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chiesi USA Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.